# Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection

> **NCT02199886** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 6 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** BIBH 1

## Key facts

- **NCT ID:** NCT02199886
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-07
- **Primary completion:** 2001-12
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02199886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02199886, "Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02199886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*